[1][2] She was appointed the Director-General of National Agency for Food and Drug Administration and Control (NAFDAC) on 3 November 2017 by the President of The Federal Republic of Nigeria, Muhammadu Buhari.
[6] Through Duquesne University, she was able to develop an anti-retroviral (HIV/AIDS) pediatric fixed-dose combination and received intellectual property on the formulations in the UK and South Africa.
[8][9] Moji Adeyeye started her career as a pharmacist at the University College Hospital, Ibadan, Oyo State, Nigeria, in 1976 and remained there till 1979.
In 2010, she was appointed Professor of Pharmaceutics, Manufacturing Science and Drug Product Evaluation, College of Pharmacy, Roosevelt University, Schaumburg, Illinois till 2018.
From 2004 to date, Moji Adeyeye has been the president, Drugs for AIDS and HIV Patients (DAHP) - a faith-based tax-exempt organization with the aim of preventing HIV/AIDS among Nigerian youths as well as prevention of mother-to-child transmission and care for orphans and vulnerable children in Lagos, Osun and Oyo States in Nigeria.
From 2004 to 2005, she was a Senior Fulbright Scholar, Faculty of Pharmacy, University of Lagos and National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.
[13] On November 11, 2017, Adeyeye was named the Director general of the National Agency for Food and Drug Administration and Control (NAFDAC), taking over from Ademola Andrew Magbojuri.